Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: A randomized, controlled study

HIV Medicine

Volumn 13, Issue 4, 2012, Pages 245-251

  Winston, A ^a   Puls, R ^b   Kerr, S J ^b,c   Duncombe, C ^c   Li, P C K ^d   Gill, J M ^e   Taylor Robinson, S D ^a   Emery, S ^b   Cooper, D A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^e Calgary Regional Health Authority   (Canada)

Author keywords

Antiretroviral therapy; Dynamics; HIV; Neurocognitive function

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXECUTIVE FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COGNITION; COGNITION DISORDERS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES; RITONAVIR; ZIDOVUDINE;

EID: 84857999639     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00962.x     Document Type: Article

References (18)

1. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13: 1249-1253.
2. Robertson KR, Robertson WT, Ford S etal. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36: 562-566.
3. Ferrando SJ, Rabkin JG, van Gorp W, Lin SH, McElhiney M. Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003; 15: 208-214.
4. Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 2008; 26: 799-819.
5. Antinori A, Arendt G, Becker JT etal. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
6. Winston A, Duncombe C, Li PC etal. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920-929.
7. Puls RL, Srasuebkul P, Petoumenos K etal. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51: 855-864.
8. Garvey LJ, Yerrakalva D, Winston A. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. AIDS Res Hum Retroviruses 2009; 25: 765-769.
9. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 2006; 21: 185-194.
10. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419-428.
11. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials 2002; 3: 279-286.
12. Gutierrez F, Navarro A, Padilla S etal. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41: 1648-1653.
13. Ciccarelli N, Fabbiani M, Giambenedetto SD etal. Prevalence and Correlates of Minor Neurocognitive Disorders in Asymptomatic HIV-infected Outpatients. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract 417].
14. Sacktor N, Skolasky RL, Tarwater PM etal. Response to systemic HIV viral load suppression correlates with psychomotor speed performance. Neurology 2003; 61: 567-569.
15. Cysique LA, Vaida F, Letendre S etal. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342-348.
16. Everall IP, Heaton RK, Marcotte TD etal. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 1999; 9: 209-217.
17. Stuss DT, Alexander MP. Executive functions and the frontal lobes: a conceptual view. Psychol Res 2000; 63: 289-298.
18. Sacktor N, Skolasky RL, Cox C etal. Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus. J Neurovirol 2010; 16: 335-341.